Análogos orales del GLP-1: perspectivas en el control glucémico y riesgo cardiorenal en pacientes con diabetes mellitus tipo 2
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico-Fontalvo, Jorge | |
| dc.contributor.author | daza arnedo, rodrigo andres | |
| dc.contributor.author | Vázquez Jiménez, Lourdes Carolina | |
| dc.contributor.author | Rodríguez-Yánez, Tomas | |
| dc.contributor.author | Raad Sarabia, Maria Isabel | |
| dc.contributor.author | TOAPANTA, NÉSTOR | |
| dc.contributor.author | Pérez, Rafael V. | |
| dc.contributor.author | Montejo-Hernández, Juan | |
| dc.contributor.author | Soler, María J. | |
| dc.date.accessioned | 2025-06-04T22:41:07Z | |
| dc.date.available | 2025-06-04T22:41:07Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | La diabetes mellitus tipo 2 (DM2) es la primera causa de inicio de terapia renal sustitutiva en la actualidad. El manejo de la DM2 en los últimos años ha pasado de un abordaje glucocéntrico a un abordaje global priorizando los tratamientos que ofrecen protección renal y cardiovascular. En este artículo revisamos en profundidad la farmacocinética y farmacodinamia del primer análogo oral del péptido similar al glucagón-1 (semaglutida oral) comparado con su formulación subcutánea. El conocimiento e implementación de dichos fármacos nos serán de gran utilidad en la práctica clínica habitual. | spa |
| dc.description.abstract | Currently, type 2 diabetes mellitus (T2DM) is the leading cause of end-stage kidney disease. The management of T2DM in recent years has moved from a glucocentric approach to a global approach with the priority of introducing treatments that offer renal and cardiovascular protection. In this article we review in depth the pharmacokinetics and pharmacodynamics of the first oral analogue of glucagon-like peptide-1 (oral semaglutide) in comparison with its subcutaneous formulation. The knowledge and implementation of these drugs will be very useful in the daily clinical practice. | eng |
| dc.format.mimetype | ||
| dc.identifier.doi | http://dx.doi.org/10.24875/NEFRO.23000052 | |
| dc.identifier.issn | 24449032 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16646 | |
| dc.identifier.url | https://www.nefrologialatinoamericana.com/frame_esp.php?id=120 | |
| dc.language.iso | spa | |
| dc.publisher | Sociedad Latinoamericana de Nefrología e Hipertensión | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Nefrología Latinoamericana | spa |
| dc.source | Nefro Latinoam. | eng |
| dc.source | Vol. 21 No. 1 Año 2024 | spa |
| dc.subject | Diabetes mellitus | spa |
| dc.subject | Análogos del receptor del péptido similar al glucagón tipo 1 | spa |
| dc.subject | Semaglutida | spa |
| dc.subject.keywords | Glucagon-like peptide 1 receptor analogues | eng |
| dc.subject.keywords | Semaglutide | eng |
| dc.title | Análogos orales del GLP-1: perspectivas en el control glucémico y riesgo cardiorenal en pacientes con diabetes mellitus tipo 2 | spa |
| dc.title.translated | Oral analogues of GLP-1: perspectives on glycemic control and cardiorenal risk in patients with type 2 diabetes mellitus | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for manage ment of type 2 diabetes. Vol. 23, Reviews in Endocrine and Metabolic Disorders. 2022 | eng |
| dcterms.references | Rico Fontalvo JE. Guía de práctica clínica para la enfermedad renal diabética. Revista Colombiana de Nefrología. 2021;8(2). | spa |
| dcterms.references | Rico Fontalvo JE, Daza Arnedo R, Raad M, Pájaro N, Correa Guerrero J, Villacob Oviedo A, et al. Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta du rol en enfermedad renal diabetica. Archivos de medicina, ISSN-e 1698-9465, Vol 17, No 2, 2021. 2021; | spa |
| dcterms.references | Lopera Vargas JM, Rico Fontalvo JE, Melgarejo R. E, Castillo Barrios GA, Ramírez Rincón A, Gomez AM, et al. Efecto de terapias farmacológicas para el control glucémico en pacientes con diabetes mellitus tipo 2 en los desenlaces vasculares. Revista Colombiana de Nefrología. 2020 Apr 13;7(1):44–59 | spa |
| dcterms.references | Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabe tes: Insights from the SUSTAIN 1–7 trials. Vol. 45, Diabetes and Meta bolism. 2019. | eng |
| dcterms.references | Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: Glucose homeos tasis and beyond. Annual Review of Physiology. 2014 | eng |
| dcterms.references | Medicina A DE, Rico-Fontalvo J, Daza-Arnedo R, Raad-Sarabia M, Pájaro-Galvis N, Correa-Guerrero J, et al. Agonistas Del Receptor Glp-1: Desde su Efecto Fisiologico en el Sistema Incretina Hasta du Rol en Enfermedad Renal DiabeticaGlp-1 Receptor Agonists: From their Physio logical Effect on the Incretine System to their Role in Diabetic Kidney Disease. 17(2). Available from: www.archivosdemedicina.com | eng |
| dcterms.references | Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. In: Progress in Molecular Biology and Translational Science. 2014. | eng |
| dcterms.references | Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012. | eng |
| dcterms.references | Tran KL, Park YI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017; | eng |
| dcterms.references | Anderson SL, Beutel TR, Trujillo JM. Oral semaglutide in type 2 diabetes. Vol. 34, Journal of Diabetes and its Complications. Elsevier Inc.; 2020 | eng |
| dcterms.references | Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for manage ment of type 2 diabetes. Vol. 23, Reviews in Endocrine and Metabolic Disorders. 2022. | eng |
| dcterms.references | Daza-Arnedo R, Rico-Fontalvo J, Raad-Sarabia M, Ramos-Clason E, Bohórquez-Rivero J, Montejo-Hernández J, et al. Semaglutida en enfer medad renal diabética: Experiencia en dos programas de salud renal en Colombia. Revista Colombiana de Endocrinología, Diabetes & Metabo lismo. 2022 Sep 21;9(3). | eng |
| dcterms.references | CHMP. ANEXO I FICHA TÉCNICA O RESUMEN DE LAS CARACTE RÍSTICAS DEL PRODUCTO. | spa |
| dcterms.references | Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Vol. 22, Diabetes Technology and Therapeutics. 2020. | eng |
| dcterms.references | Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(468). | eng |
| dcterms.references | Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue sema glutide in humans and nonclinical species. European Journal of Pharma ceutical Sciences. 2017;104. | eng |
| dcterms.references | Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial. JAMA - Journal of the American Medical Association. 2017;318(15). | eng |
| dcterms.references | Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42(12) | eng |
| dcterms.references | Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA - Journal of the American Medical Association. 2019;321(15). | eng |
| dcterms.references | Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, et al. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(3). | eng |
| dcterms.references | Marso SP, Daniels GH, Frandsen KB, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016; | eng |
| dcterms.references | Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018; | eng |
| dcterms.references | Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lan cet. 2019; | eng |
| dcterms.references | Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Dia betes. New England Journal of Medicine. 2016; | eng |
| dcterms.references | Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019; | eng |
| dcterms.references | McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, et al. Effects of oral semaglutide on cardiovascular outcomes in indivi duals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteris tics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7). | eng |
| dcterms.references | Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular Mechanisms of Diabetic Kidney Disease. Vol. 23, International Journal of Molecular Sciences. MDPI; 2022. | eng |
| dcterms.references | Rico-Fontalvo J, Aroca-Martínez G, Daza-Arnedo R, Cabrales J, Rodríguez-Yanez T, Cardona-Blanco M, et al. Novel Biomarkers of Dia betic Kidney Disease. Vol. 13, Biomolecules | eng |
| dcterms.references | Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacoki netics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet. 2018;57(12). | eng |
| dcterms.references | Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-con trolled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; | eng |
| dcterms.references | Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9). | eng |
| dcterms.references | Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 dia betes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 2019;394(10192). | eng |
| dcterms.references | Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-la bel, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7 | eng |
| dcterms.references | Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PioNEER 8 trial. Diabetes Care. 2019;42(12). | eng |
| dcterms.references | Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endo | eng |
| dcterms.references | Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5) | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |